Maurizio D’Incalci

Maurizio D’Incalci was born in Milan in 1952 and obtained his Medical Degree cum Laude from the University of Milan in 1978. After specializing in pharmacology at the Mario Negri Institute of Milan and in oncology at the University of Genoa, he worked in the Laboratory of Molecular Pharmacology of the National Cancer Institute in Bethesda, MD, USA. Since 1986 he has been chief of the Laboratory of Cancer Chemotherapy at the Mario Negri Institute and since 1996 he has become chief of the Department of Oncology at the Mario Negri Institute. He has been President of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer (EORTC). From 1994 to 1996 he was Chairman of the New Drug Development Coordinating Committee and from 1997 to 2000 he was Chairman of the Research Division of the EORTC. He has been member of the Board of the EORTC from April 2000 to 2003. Since 1995 he is member of the Board of Directors of the Nerina and Mario Mattioli Onlus Foundation. From 1997 he is the Preclinical Coordinator of the Southern Europe New Drug Organization (SENDO) and from 2005 he is the Chairman of the New Agents Committee. From 2003 to 2013 he is member of the Ethic Committee of the Centro di Riferimento Oncologico (CRO) of Aviano. From 2006 he is president of the Scientific Committee of the Mario Negri Gynecologic Oncology group (MaNGO). From 2007 he is member of the Scientific Committee of the Italian Association for Cancer Research (AIRC). From 2009 to 2013 he is member of the Board of Directors of the Italian Cancer Society (SIC). From 2010 he is member of the Scientific Committee of the Fondazione Buzzi Unicem Onlus for the research, diagnosis and cure of malignant mesothelioma. From November 2013 he is member of the Ethic Committee of the “Fondazione del Piemonte per l’Oncologia – IRCCS” of Candiolo (Turin). From 2014 he is member of the Board of Directors of the Controlled Release Society (CRS) Italy Chapter, as representant of the medical-biology area. From September 2014 he is member of the IFOM Ethics Committee for Biomedical Research. He is on the editorial board of many international cancer-related scientific journals and from September 2000 to December 2010 he has been Editor for Experimental Oncology of the European Journal of Cancer. Dr D’Incalci is author of more than 470 papers on cancer pharmacology, preclinical and clinical drug development published in peer reviewed international journals, and of several chapters in books on cancer chemotherapy and pharmacology.